Abstract Traditional tissue engineering approaches to the restoration of orthopaedic tissues promise to be expensive and not well suited to treating large numbers of patients. Advances in gene transfer technology offer the prospect of developing expedited techniques in which all manipulations can be performed percutaneously or in a single operation. This rests on the ability of gene delivery to provoke the sustained synthesis of relevant gene products in situ without further intervention. Regulated gene expression is also possible, but its urgency is reduced by our ignorance of exactly what levels and periods of expression are needed for specific gene products. This review describes various strategies by which gene therapy can be used to expedite the repair and regeneration of orthopaedic tissues. Strategies include the direct injection of vectors into sites of injury, the use of genetically modified, allogeneic cell lines and the intra-operative harvest of autologous tissues that are quickly transduced and returned to the body, either intact or following rapid cell isolation. Data obtained from pre-clinical experiments in animal models have provided much encouragement that such approaches may eventually find clinical application in human and veterinary medicine.
Introduction
Injuries to the skeletal system are common and the damaged tissues may not heal spontaneously. Articular cartilage, meniscus and intra-articular ligaments, for instance, have little intrinsic ability to repair. Long bones, on the other hand, normally heal fractures very efficiently; nevertheless, approximately 5-10 % of fractures result in non-unions. Moreover, large segmental osseous defects and cranial defects do not heal in adults. Extra-articular ligaments and tendons usually heal, but the repair tissue is structurally and functionally inferior to undamaged tissue. In all cases, the ability for spontaneous repair declines with age.
A number of diseases of the skeletal system also lead, directly or indirectly, to loss of structural integrity. Osteoarthritis (OA), for instance, produces large lesions in the articular cartilage and tumour resection often removes considerable amounts of tissue.
Although certain surgical techniques and engineered devices can mitigate some of these problems, the present trend is to seek biological solutions that promise to restore tissue in a more natural, functional and permanent manner [1] . Tissue engineering has attracted much attention. This has traditionally involved the removal of host cells followed by their in vitro expansion, seeding onto a scaffold, incubation in a bioreactor and implantation (Fig. 1a) . While much progress has been made in this endeavour it is cumbersome and expensive, requiring two invasive procedures, one to harvest cells and the other to implant the engineered tissue. Because the patient population is potentially so large, there is a need for expedited, affordable procedures. It has long been recognised that gene transfer has the potential to enhance the process of tissue engineering [2] [3] [4] . Our group is exploring methods that can be implemented in a minimally invasive fashion or during a single operation (Fig. 1b) . The key requirement is that nothing leaves the operating theatre. A favoured strategy attempts to provoke the intrinsic regenerative potential of the tissue in question, an approach that has been termed "facilitated endogenous repair" [5] . Gene transfer is a key component of this approach.
Advantages of gene delivery
Although gene therapy is most often considered in the setting of genetic diseases, it also has a potential role in treating acquired conditions. In this context, it serves as a delivery system for the product of the gene in question. This might be a protein, such as a transcription factor, enzyme or growth factor, or a species of non-coding RNA that regulates the expression of other genes. There are several advantages to delivering a gene rather than its cognate gene product, whether protein or RNA.
Delivery of a gene product usually has brief biological influence, because the product is rapidly cleared. To achieve sustained effects it is necessary to apply repeatedly the molecules in question or implant some sort of controlled delivery device. Much research focuses on the latter, but has so far had limited success in the regenerative orthopaedic arena [6] .
Gene transfer offers several advantages for facilitated endogenous repair. The first relates to the limited opportunity for cell manipulation during a single, expedited procedure. Based on conversations with orthopaedic colleagues, it seems that a single operation allows up to two hours to complete all [1] , as modified from [5] , with permission necessary procedures. Whatever occurs during this short window needs to have a prolonged downstream effect during the ensuing weeks or months during which new tissue is formed.
Advances in gene transfer technology mean that it is now possible to transduce cells rapidly. Once a gene or cDNA has been transferred to the cell nucleus it will continue to produce the gene product for as long as the cell exists, and the gene remains present and expressed. This offers the possibility of not only sustained expression, but also regulated expression in which synthesis of the encoded transgene product can be regulated temporally and quantitatively by small molecules or other such signals. It is also possible to envision endogenous control of transgene expression by local cues. Urgency to invest in regulated gene expression is reduced by lack of information concerning the expression profiles required of specific gene products. Nearly all studies where gene therapy is used for regenerative orthopaedics have used strong constitutive promoters and, apart from the work of Gazit and colleagues [7, 8] , regulated gene expression remains little explored.
Gene transfer also facilitates the delivery of gene products with intracellular sites of action. Important examples include transcription factors and non-coding RNA. Although proteins can be modified to include protein transduction domains and RNA can be delivered by transfection, these methods can be inefficient and, as noted above, need to be repeated in anything beyond an acute condition.
Unlike many of the recombinant proteins used clinically, proteins synthesised following gene delivery are more likely to have undergone authentic post-translational modification. This often leads to greater biological activity and reduces concerns over possible immunogenicity. Moreover, purification, sterilisation and storage of the protein are no longer issues, although these matters still arise for the vectors used for gene delivery, described next.
Gene delivery vectors
Vectors are the vehicles that transfer exogenous DNA (transgenes) into target cells, with transport to the nucleus of the cell where gene expression is initiated. The most powerful vectors are derived from viruses, taking advantage of the innate ability of viruses to deliver their own genomes efficiently to the cells they infect. To create a vector for gene therapy, the viral genome is modified to remove sequences that contribute to virulence and disease thereby creating genetic room for therapeutic sequences. An increasing number of viruses have been modified in this fashion [9] . Those that have advanced to testing in human clinical trials [10] include retrovirus, lentivirus, adenovirus, vaccinia virus, adenoassociated virus (AAV), herpes simplex virus, and measles virus, among others. Gene transfer using a virus is known as transduction.
Because viral vectors are often complicated to manufacture, expensive to produce and attract safety concerns, there is continuing interest in using non-viral vectors [11] . They raise far fewer safety issues than viral vectors, an important consideration in the context of regenerative orthopaedics, which addresses non-lethal conditions; they are also much cheaper to produce. Non-viral vectors can be as simple as naked DNA. Transfer efficiency can be increased by combining the DNA with a polymeric carrier or by using physical stimuli such as electroporation or sonication. Although non-viral vectors hold much potential, in our experience they remain inefficient and transgene expression is transient. For this reason we have focussed on viral vectors. Gene transfer using a non-viral vector is known as transfection.
Safety is of paramount concern in the context of regenerative orthopaedics, which places constraints on the selection of viral vectors. The risk of insertional mutagenesis will make regulatory approval very difficult for so-called integrating viruses, which insert their genomes into those of the cells they infect. Retroviruses and lentiviruses (a type of retrovirus) are examples of integrating viruses used for gene therapy. One potential advantage of viral integration is the transmission of the transgene to daughter cells after division of the host cell, thereby aiding long-term transgene expression. This, however, may not be necessary for the repair and regeneration of orthopaedic tissues; indeed, prolonged production of a growth factor, for example, could be detrimental. Lentiviruses have been engineered to become non-integrating while retaining their high transduction efficiency.
AAV has the advantage of causing no known disease. Recombinant AAV transduces both dividing and nondividing cells, and persists as an episome in the nuclei of transduced cells for extended periods. The disadvantages of this vector include its small DNA carrying capacity and expensive, complicated manufacture.
Vectors derived from baculoviruses, which normally infect insects, are gaining in popularity. They have large DNA genomes, but are easy to manipulate genetically and can be readily produced at high titers. Very high levels of transgene expression can be achieved. Their application to the regeneration of bone and cartilage has been reviewed recently by Lin et al. [12] .
Our group has favoured vectors based on adenovirus for regenerative orthopaedics. This virus infects many different types of dividing and non-dividing cells. Expression of transgenes is usually high. First and second generation recombinant adenovirus vectors are straightforward to produce and have been used in over 400 human clinical trials [10] . Under normal circumstances, in vivo transgene expression using early generation adenovirus vectors is high for one to two weeks and then declines, with little transgene expression after three to six weeks. These kinetics may be ideal for many applications in regenerative orthopaedics.
Gene delivery strategies
Regardless of the vector that is used, genes may be transferred in an in vivo or ex vivo fashion. The traditional tissue engineering approach to repair (Fig. 1a) lends itself to ex vivo gene transfer, and this has been evaluated experimentally. However, unless there are special circumstances relating, for example, to cost or a need for intracellular location of the gene product, it may be more convenient to expose the cells to recombinant proteins or RNA transfection in the bioreactor than to attempt gene delivery.
There is increasing interest in foregoing a prolonged bioreactor step and instead implanting expanded autologous cells, such as mesenchymal stem cells (MSCs), on suitable scaffolds without further differentiation of the cells. Tissue formation and maturation then occur in vivo. This strategy also provides the opportunity for ex vivo gene delivery and the two technologies complement each other well in this regard. The drawback, however, is the need to recover and expand each individual's cells in a good manufacturing practice (GMP) facility, which makes the approach tedious and expensive. One way around this is to use allograft cells from a universal donor (Fig. 2) . As described later in this review, such an approach is being evaluated clinically in the context of cartilage repair. The degree to which an allograft response limits the usefulness of this general strategy remains to be seen.
In vivo gene delivery is simpler, but complicates the regulatory pathway because infectious agents are introduced directly into the body. Moreover, many viral vectors are immunogenic and humans often have pre-existing immunity to the most common viruses used for gene transfer. Even if they do not, the initial application will generate immunity and thus complicate repeat dosing, should this be necessary. Another limiting factor is the need for local host cells that can be transduced by the injected vectors. It is likely that gene therapy will be reserved recalcitrant clinical cases, often associated with considerable cell death in and around the injury site. Under these conditions, an in vivo approach may be ineffective. A big advantage of ex vivo delivery is its ability to deliver cells in addition to genes.
Facilitated endogenous repair
Based on the discussion so far, the approach favoured by our group requires a strategy whereby genetically modified cells can be introduced intra-operatively or percutaneously into a defect within a two hours window (Fig. 1b) . Figure 2 illustrates different ways in which this might be accomplished.
In vivo delivery
As noted, in vivo gene delivery offers a straightforward approach to tissue regeneration that can be accomplished percutaneously [13] or intraoperatively [14] .
This strategy has been applied to the healing of segmental osseous defects in rat [15] [16] [17] , lapine [18] [19] [20] [21] [22] , equine [23] [24] [25] and ovine [26, 27] models. Studies in the rat explored the direct, intra-lesional injection of recombinant adenovirus carrying cDNA encoding human bone morphogenetic protein-2 (Ad. BMP-2). This showed good efficacy in about half of the animals, but delayed union in the others; the latter had a prominent band of cartilage suggesting a possible pseudarthrosis. This method was ineffective in a sheep tibial defect [27] . Of interest, it had a beneficial effect in sheep treated with high doses of methylprednisolone as part of a protocol to induce osteoporosis [26] . Among the explanations of this phenomenon is the possibility that the glucocorticoid had suppressed the immune response to the virus. In contrast to sheep, good results have been reported for the healing of osteochondral defects in the horse after direct application of Ad. BMP-2 or Ad. BMP-6 [23] . Delaying the introduction of the virus seems advantageous, possibly because it allows time for progenitor cells to enter the defect [15, 23] .
Cucchiarini and Madry [28] have explored direct gene delivery in the context of cartilage repair. Using a rabbit model, these investigators have shown it possible to deliver recombinant AAV vectors directly to cells as they enter full thickness cartilagenous defects in rabbit knees. Particularly impressive results were found with fibroblast growth factor-2 (FGF-2) cDNA as the transgene [29] . This strategy could be used in conjunction with microfracture to accelerate healing and enhance the quality of the repair cartilage. AAV is of particular interest in cartilage repair strategies, because it is small enough to penetrate the matrix of cartilage and transduce cells in situ [30, 31] . In this context it has been evaluated in vitro for possible utility in the repair of meniscal lesions [32] . Adenovirus, in contrast, penetrates meniscus to a very limited degree, even after injection into the matrix [33] .
The nucleus pulposus of the intervertebral disc supports the in situ transduction of cells by recombinant adenovirus [34] and AAV [35] . Very promising results have been obtained in preventing lapine models of disc degeneration using AAV to deliver cDNAs encoding combinations of BMP-2 and tissue inhibitor of metalloproteinases (TIMP)-1 [35] or BMP-7 and the transcription factor sox 9 [36] . Additional data suggest that the interleukin-1 receptor antagonist (IL-1Ra) cDNA could be useful in preventing disc degeneration [37, 38] . This is interesting in view of the AAV.IL-1Ra vector that is moving towards clinical trials for OA [39] .
As reviewed in references [40, 41] , in vivo gene delivery to ligament and tendon has been reported for adenovirus, lentivirus, AAV and several non-viral formulations.
Use of allograft, universal donor cells
As noted above, the approach of using transduced allograft cells is in clinical trials. Early research using rabbit models confirmed that genetically modified, allogeneic chondrocytes could be transferred to cartilagenous defects where they continue to express marker genes in the host defect site [42, 43] . Subsequent studies confirmed that use of a cDNA encoding a chondrogenic factor, such as insulin-like growth factor-1 (IGF-1) [44] [45] [46] [47] , FGF-2 [48] or bone morphogenetic protein-7 (BMP-7) [49, 50] could improve repair of a cartilagenous defect by autologous cells.
These approaches have been taken into human clinical trials by the companies Kolon in Korea and TissueGene in the USA (clinicaltrials.gov identifier NCT01671072). The technology uses lines of articular chondrocytes grown from finger joints recovered surgically from a newborn child with polydactyly. One cohort of cells was transduced with a retrovirus carrying cDNA encoding transforming growth factor-β 1 (TGF-β 1 ). Because the virus vector is integrating, the cells are irradiated prior to use to prevent them from dividing. This eliminates the possible development of tumours, should insertional mutagenesis have occurred. To amplify and extend the effects of the irradiated cells, they are mixed with untransduced, unirradiated cells before use.
These cells have been used in two different ways. In patients with OA, cell suspensions are injected directly into the joint [51] . For cartilage injuries, the cells are implanted into defects in a manner analogous to articular chondrocyte implantation. Both applications have completed phase II studies in humans and are about to enter phase III trials.
Allografted cells have also been explored in pre-clinical studies of bone healing. Lieberman's group pioneered the use of genetically modified, autologous, marrow-derived MSCs for healing large segmental defects [52, 53] . Using a rat model, Tsuchida et al. [54] explored the possibility of employing allografted MSCs. Like Lieberman, they used a recombinant adenovirus vector (Ad. BMP-2) to deliver a human BMP-2 cDNA to marrow-derived MSCs. The data showed that allografted cells were only able to repair the defect when transient immunosuppression with FK506 was imposed.
One way to overcome this impediment to the use of allograft cells is indicated by the recent publication of Sonnet et al. [55] who protected the cells by encapsulation in poly (ethylene glycol) diacrylate. When protected donor cells were transduced with Ad. BMP-2 and implanted as encapsulated microspheres into a rat femoral defect, healing occurred rapidly and efficiently. However, in this configuration, the implant serves only as a local source of BMP-2, with no contribution of donor cells to regenerate. The relative importance of donor cells as suppliers of trophic factors or as sources of new tissue is much debated and remains unresolved.
Rapid cell isolation and manipulation
MSCs are a popular source of progenitor cells for the repair of orthopaedic tissues. Lieberman's group developed an expedited procedure in which populations of cells enriched for MSCs are recovered from bone marrow, transduced with lentivirus carrying BMP-2 cDNA and returned to defects on a collagenous scaffold. Proof of principle has been demonstrated in rat segmental defects [56] .
We have developed an analogous approach using fat as the starting material. In a single session, this can be rapidly recovered, digested with collagenase, transduced with Ad. BMP-2, encapsulated in fibrin and returned to segmental defects in rats [57] .
Biopsy, modify and reimplant intact tissue An alternative approach makes use of tissues that can be readily biopsied and genetically modified without the need to isolate cells. If they also have scaffolding properties, they can then be inserted into the defect without further manipulation. Skeletal muscle, fat and marrow are of interest in this regard (Fig. 3) , with marrow acquiring scaffolding properties after it clots.
Skeletal muscle is of particular interest in the context of bone healing, because of the genetic disease fibrodysplasia ossificans progressiva (FOP) in which skeletal muscle spontaneously turns to bone. FOP is caused by a mutation that increases responsiveness to BMP-2 [58] . This suggests that bone forms intramuscularly in skeletal muscle in humans in response to a sustained BMP-2 signal. The fact that this occurs in humans is especially important, given the deficiencies of animal models and species differences in response to growth factors such as BMP-2. The osteogenic predeliction of muscle is also demonstrated by the high incidence of heterotropic ossification following blast injuries [59] and certain types of surgery [60] .
The value of this has been demonstrated in a rat model, where muscle biopsies were recovered from donor rats, transduced with Ad. BMP-2 and inserted into critical size segmental defects [61] . Reliable and rapid healing was achieved.
Fischer rats were used in these experiments because these animals constitute a syngeneic strain allowing tissue transfer between individuals as a surrogate for autologous grafting. Sprague-Dawley rats are not syngeneic and the procedure was considerably less effective in this strain, indicating the sensitivity of the osteogenic response to immune activation as shown by the work of Tsuchida et al. [54] , noted earlier.
Genetically modified fat biopsies were also effective in many animals, but this was less reliable than when using muscle.
Because healing of segmental osseous defects with genetically modified fat and muscle was found to occur through an endochondral mechanism, we tested whether these grafts could also heal cartilage lesions. Preliminary experiments in rabbits suggested that this was indeed the case [61] .
Preliminary experiments have been performed using genetically modified muscle for tendon healing Achilles tendon in rats [41] .
The concept of using clotted marrow arose in the context of cartilage repair where microfracture techniques are commonly used to heal cartilage lesions. As a result of microfracture, a clot forms in the lesion; progenitor cells enter from the marrow and differentiate into cells that resemble chondrocytes but produce a fibrocartilagenous repair tissue that eventually fails. We suggested that these cells could form authentic, durable articular cartilage if they were provided with the appropriate morphogens delivered genetically by adenovirus incorporated into the clot. Moreover, placing clotted marrow directly into the lesion promises to accelerate the healing process that would otherwise be delayed by the time taken for cells to migrate into the lesion from the marrow.
To test these possibilities, bone marrow was recovered from rabbits, mixed with adenovirus vectors and allowed to from a clot, known as a "gene plug" [62] . The properties of the gene plug are such that it can be press-fit into the lesion; Fig. 3 Facilitated, endogenous repair using genetically modified muscle, fat and bone marrow. Modified from [5] , with permission moreover the shape and dimensions of the vessel in which clotting occurred could be selected to match the requirements of the defect. Preliminary experiments in rabbits confirmed efficient gene transfer to cells within the clot, possibly reflecting the high transduction efficiency of adenovirus when associated with fibrin [63] .
This concept was further extended to the healing of partial thickness defects in a sheep model, using TGF-β 1 as the transgene [64] . This confirmed the feasibility of the technology in large animals and led to improved healing of the cartilage.
Blood clots incorporating adenovirus have been explored for gene delivery to meniscus [33] .
Perspective
In addition to being scientifically sound and clinically effective, advanced technologies in regenerative orthopaedics need to be affordable, expeditious and capable of treating large numbers of individuals. By avoiding the ex vivo cultivation of autologous cells, the methods described in this review eliminate several of the bottlenecks and costs associated with traditional, tissue engineering approaches. Nevertheless, use of gene therapy raises new ones [39, 65] . However, the field of gene therapy is rapidly maturing and the EMA recently approved its first human gene therapy, glybera, for the treatment of lipoprotein lipase deficiency [66] . As more protocols advance to the clinic, the pathway for approval will become clearer and progress will be expedited. The technologies described in this review attempt to minimise regulatory issues and facilitate translation. Genetically modified, allograft chondrocytes are poised to enter phase III clinical trials; additional trials in the gene therapy of arthritis have completed phase I [67] [68] [69] and II [70] and two additional protocols for arthritis are moving towards clinical trials [39] . As momentum builds, progress should accelerate and the scope of orthopaedic gene therapy broaden.
